Cargando…
mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders
Tuberous sclerosis complex (TSC) is a rare autosomal dominant genetic disorder that affects multiple organ systems throughout the body. Dysregulation of the mammalian target of rapamycin (mTOR) pathway is implicated in the disease pathology, and evidence exists to support the use of mTOR inhibitors...
Autores principales: | Franz, David N., Capal, Jamie K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348752/ https://www.ncbi.nlm.nih.gov/pubmed/28288694 http://dx.doi.org/10.1186/s13023-017-0596-2 |
Ejemplares similares
-
mTOR Inhibitors in Tuberous Sclerosis Complex
por: Curatolo, Paolo, et al.
Publicado: (2012) -
Perfect match: mTOR inhibitors and tuberous sclerosis complex
por: Luo, Cong, et al.
Publicado: (2022) -
RARE-25. RETINAL ASTROCYTOMA mTOR INHIBITOR THERAPY IN TUBEROUS SCLEROSIS MOSAICISM
por: Evans, Naomi, et al.
Publicado: (2020) -
The Putative Role of mTOR Inhibitors in Non-tuberous Sclerosis Complex-Related Epilepsy
por: Goldstein, Hannah E., et al.
Publicado: (2021) -
YAP enters the mTOR pathway to promote tuberous sclerosis complex
por: Liang, Ning, et al.
Publicado: (2015)